Discontinued — last reported Q1 '19
Vertex Pharmaceuticals OCI Available-for-Sale Securities, Tax increased by 52.4% to -$1.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 94.5%, from -$18.30M to -$1.00M.
Fluctuations indicate changes in the tax-adjusted value of the company's liquid investment holdings.
This represents the tax impact associated with unrealized gains or losses on available-for-sale debt securities that are...
Specific to companies with large cash reserves invested in marketable securities; varies based on the company's investment strategy and tax position.
is_ms_oci_afs_securities_tax| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | -$675.00K | -$675.00K | -$675.00K | -$675.00K | $1.50M | -$18.30M | -$2.10M | -$1.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +322.2% | <-999% | +88.5% | +52.4% |
| YoY Change | — | — | — | — | +322.2% | <-999% | -240.0% | +94.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.